Montelukast sodium ...

Montelukast sodium CAS No. 151767-02-1 CAS NO.151767-02-1
Montelukast sodium CAS No. 151767-02-1 CAS NO.151767-02-1
Montelukast sodium CAS No. 151767-02-1 CAS NO.151767-02-1
Montelukast sodium CAS No. 151767-02-1 CAS NO.151767-02-1

Montelukast sodium CAS No. 151767-02-1 CAS NO.151767-02-1

Min.Order / FOB Price:Get Latest Price

1 Kilogram

FOB Price:USD 1.0000 -3.0000

  • Min.Order :1 Kilogram
  • Purity: 99%
  • Payment Terms : T/T,,MoneyGram,Other

Keywords

Montelukast sodium mk-476 151767-02-1

Quick Details

  • Appearance:crystal, powder
  • Application:Pharmaceutical intermediates
  • PackAge:as your request
  • ProductionCapacity:10|Kilogram|Day
  • Storage:stay in dry, cool and well-sealed
  • Transportation:EMS,HK EMS,FEDEX,DHL,TNT

Superiority:

 

Reason for Choosing us:

1): Superior Quality and Competitive Price:  

Our company is a renowned pharmaceutical manufacturer with more than 15 years experiences in China and all powders are supplying from our factory directly.

2): Fast ,Safe and Well Disguised Delievery: 

Well-trained and disciplined packing team and sufficient stock ensure the parcel can be delieveried to your hand fastly and safely by DHL, TNT, FedEx, HKEMS, UPS, etc.

3): Experienced in Exporting:

We have clients throughout the world. Products have been exported to Germany, Norway, Poland, Finland, Spain, UK, France, Russia, USA, Brazil, Mexico, Australia, Japan, Korea, Thailand, Indonesia, Uruguay and many other countries.  Custome pass rate ≥99%

4): Flexible Payment terms:

T/T,Western Union,Money Gram,Bitcoin. There will always be a term that is convient to you.

5): Warmhearted Customer Service and After-sale Service:

The parcel's photos and tracking numbers will be sent to you once it is prepared. Any of your questions would be solved for the first as soon as possible.

Details:

  • Details

     

     
    Montelukast sodium Basic information
    <a effect"="" style="margin: 0px 10px 0px auto; padding: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 12px; border: 0px; color: rgb(0, 51, 153); outline: none; display: inline-block; overflow: hidden;">Pharmacological effect Application
    Product Name: Montelukast sodium
    Synonyms: singulair;MONTELUKAST NA;MONTELUKAST SODIUM;mk-476;2-[1-[[1-[3-[2-[(7-chloro-2-quinolyl)]vinyl]phenyl]-3-[2-(1-hydroxy-1-methyl-ethyl)phenyl]-propyl]sulfanylmethyl]cyclopropyl]acetic acid sodium salt;1-[1-[[[(1R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic;MK-476, Singulair;Montelukast, Sodium Salt
    CAS: 151767-02-1
    MF: C35H35ClNNaO3S
    MW: 608.17
    EINECS:  
    Product Categories: Active Pharmaceutical Ingredients;APIs;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;Isotope Labeled Compounds;Pharmaceutical intermediates;DIOXYLINE;Other APIs;Inhibitors

     

    Montelukast sodium Chemical Properties,Usage,Production

     

     
    Pharmacological effect
    Cysteinyl leukotrienes (LTC4, LTD4, LTE4) is a eicosane-type substance released by various kinds of cells including mast cells and eosinophils with strong inflammatory effect. These important asthma pre-inflammatory mediators can bind to the Cysteinyl leukotriene receptors (CysLT) identified in the human airways, resulting in a variety of airway responses including bronchoconstriction, mucus secretion, increased vascular permeability, and eosinophil accumulation. 
    Montelukast sodium is an orally active selective leukotriene receptor antagonist that can specifically inhibit the cysteinyl leukotriene receptor. It was successfully developed by the Merck Company (German) and had entered into market in Canada, Finland, and Mexican in 1997. It is suitable for the prevention and long-term treatment of adults and children asthma, including the prevention of daytime and nighttime asthma symptoms, the treatment of asthma patients who are aspirin-sensitive and prevention of exercise-induced bronchial contraction, it can also be used to relieve the seasonal allergic rhinitis symptoms of 15 year-old or over 15 year-old patients whose symptoms are invalid and intolerant to other treatment. 
    Montelukast is a selective leukotriene receptor antagonist and has been approved for the oral administration treatment of asthma and allergic rhinitis. It is also a potent oral preparation that can significantly improve the inflammatory indicators. Biological determination of biochemistry and pharmacology has showed that montelukast sodium has a high affinity and selectivity to the CysLT1 receptors (compared with other kinds of pharmacologically important airway receptors such as prostanoid, cholinergic and β- adrenergic receptors). Montelukast can effectively suppress the physiological effects caused by the binding between LTC4, LTD4 and LTE4 receptor and CysLT1 receptor without any receptor agonistic activity. There is the secondary type of cysteinyl leukotriene receptor (CysLT2) presented in the lungs cysteinyl leukotriene receptor but may be limited to the blood vessels. So far, researchers haven’t cloned two receptors so the situation of CysLT receptor is illustrated through binding assay and pharmacological analysis. It has been now thought that montelukast does not antagonize CysLT2 receptors.
    The above information is edited by the chemicalbook of Dai Xiongfeng.
    Application
    It can be applied to alleviate the symptoms caused by allergic rhinitis.
    Usage
    A selective leukotriene D4-receptor antagonist. Used as an antiasthmatic
    Usage
    antiinfective
    Usage
    A potent and highly selective CysLT1 receptor antagonist, without demonstrated CysLT2 activity

 

Related Searches

Confirm to collect the product to my collection?

OKCancel

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View